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Background:  The  characteristics,  in-hospital  management,  and  outcomes  of  patients  hospitalized  with
worsening  heart  failure  (HF)  have  been  described  by  large-scale  registries  performed  mainly  in  the  USA
and  Europe.  However,  little  information  is  available  in  Japan.  We  thus  clariﬁed  the  characteristics  and  clin-
ical  status  as well  as in-hospital  management  and  outcomes  among  patients  hospitalized  with  worsening
HF  in Japan  and  compared  them  with  those  reported  in  previous  studies.
Methods: The  Japanese  Cardiac  Registry  of  Heart  Failure  in Cardiology  (JCARE-CARD)  studied  prospectively
the  characteristics  and  treatments  in  patients  hospitalized  with  worsening  HF.  From  the  total  cohort  of
JCARE-CARD,  1677  patients  were  randomly  selected  and  their  detailed  data  during  acute  phase  were
collected  as  another  registry  database  in  the  present  study.  The  characteristics,  in-hospital  management,
and  outcomes  were  analyzed.
Results: The  mean  age  was  70.7  years  and  59.4%  were  male.  Etiology  was  ischemic  in 34.0%  and  mean  left
ventricular  ejection  fraction  was  42.5%.  Carperitide  was  highly  used  as  in-hospital  management  in Japan
(33.5%)  compared  to  the  use of nesiritide  in  the  USA  (8–11%).  The  use of  angiotensin-converting  enzyme
inhibitors  was  lower  and  angiotensin  II receptor  blockers  (ARB)  were  more  commonly  used in this  study
compared  to  other  studies  in  the  USA  and  Europe.  In-hospital  crude  mortality  rate  was  comparable  among
studies  (4–8%),  however,  length  of  stay  was  longer  in Japan  (15–20  versus  4–9 days).
Conclusions: The  characteristics,  clinical  status,  and  laboratory  data  on  admission  in  patients  hospitalized
with  worsening  HF  were  similar  between  the present  study  and  previous  Japanese  and western  studies.
Management  was  also  similar  except  for  higher  use of  carperitide  and  ARB.  The  most  striking  difference
between  Japanese  registries  and those  from  the  USA  and  Europe  was  the  longer  length  of  stay.
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ntroductionHeart failure (HF) is a complex condition with substantial mor-
idity and mortality and healthcare needs and economic burden for
epeated worsening [1]. Current clinical proﬁles of patients hos-
italized with worsening HF have been well documented based
DOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2013.05.011.
∗ Corresponding  author at: Department of Cardiovascular Medicine, Hokkaido
niversity  Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-
638, Japan. Tel.: +81 11 706 6970; fax: +81 11 706 7874.
E-mail  addresses: htsutsui@med.hokudai.ac.jp, cvsecret@med.hokudai.ac.jp
H. Tsutsui).
1 For the JCARE-CARD Investigators.
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.03.009anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
on large-scale in-patient hospital registries [2–4]. The EuroHeart
Failure survey (EHFS) [5–9] in Europe, the Acute Decompensated
Heart Failure National Registry (ADHERE) [3], and the Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients
With Heart Failure (OPTIMIZE-HF) [10,11] in the USA have provided
valuable information on the clinical characteristics and outcomes
in patients hospitalized for worsening HF. However, they did not
include important information on clinical status, laboratory data,
and cardiac function on admission [12]. Consequently, the clini-
cal characteristics of patients hospitalized with worsening HF have
not been well described. Furthermore, large-scale registries were
performed mainly in the USA and Europe. However, the manage-
ment strategies of worsening HF may  be different from countries
vier Ltd. All rights reserved.
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ccording to healthcare system, only little information has been
vailable from the Acute Decompensated Heart Failure Syndromes
ATTEND) registry which is currently under way in Japan [13]. Thus,
ore complete understanding of characteristics, in-hospital man-
gement, and outcomes of patients hospitalized with worsening
F in an observational database is deﬁnitely needed in Japan. This
ould be needed also for the optimal management of Japanese
atients hospitalized with worsening HF [14].
The Japanese Cardiac Registry of Heart Failure in Cardiology
JCARE-CARD) studied prospectively the characteristics and man-
gement in a broad sample of patients hospitalized with worsening
F in Japan and the outcomes including death and rehospitalization
ere followed [15–26]. The JCARE-CARD enrolled 2675 patients
dmitted with worsening HF in a web-based registry at 164 partic-
pating hospitals with an average of follow-up of 2.2 years. In this
tudy, we randomly selected 1677 patients from a total cohort and
ollected the acute-phase data during hospitalization in detail as
nother registry database.
The  objectives of this study were to clarify the characteristics of
atients, clinical status on admission, management during hospi-
alization, and in-hospital outcomes in patients hospitalized with
orsening HF and to compare them with previous registry data
ncluding ATTEND [13] in Japan, ADHERE [3] and OPTIMIZE-HF
10,11] from the USA, and EHFS-II [8,9] from Europe.
ethods
The details of the JCARE-CARD have been described previously
15,19,20,24,27]. Brieﬂy, it registered the patients hospitalized due
o worsening HF as the primary cause of admission. The study hos-
itals were encouraged to register the patients as consecutively
s possible. For each patient, baseline data included (1) demogra-
hy; (2) causes of HF; (3) precipitating causes; (4) comorbidities;
5) complications; (6) clinical status; (7) electrocardiographic and
chocardiographic ﬁndings; (8) laboratory data; and (9) treatments
ncluding discharge medications. The data were entered using a
eb-based electronic data capture (EDC) system licensed by the
CARE-CARD (www.jcare-card.jp). The status of all patients was
urveyed  at discharge of index hospitalization and at least 1 year
fter hospital discharge. Therefore, JCARE-CARD primarily collected
he long-term follow-up data of HF patients hospitalized due to its
orsening.
To clarify the characteristics, management, and outcomes of
cute HF at the time of hospital admission, the present study col-
ected these additional data retrospectively in detail as another
egistry data in 1677 patients selected from a total of 2675 patients
egistered in JCARE-CARD. Out of 164 participating hospitals in
CARE-CARD, 83 hospitals were randomly selected and all patients
egistered from these hospitals were included in the present
tudy. Patients in the present study were representative of the
otal cohort of patients in JCARE-CARD except for lower blood
ressure at discharge (systolic blood pressure 115.6 ± 18.7 mmHg
ersus 117.0 ± 18.6 mmHg, p = 0.021 and diastolic blood pressure
5.2 ± 11.8 mmHg  versus 66.0 ± 11.6 mmHg, p = 0.026). The present
tudy analyzed the acute phase data of (1) characteristics (age, sex,
ause of HF, medical history, and therapeutic procedures), (2) vital
igns and laboratory data on admission (New York Heart Associ-
tion [NYHA] functional class, symptoms and signs, chest X-ray,
nd blood chemistry), (3) medication use (angiotensin-converting
nzyme [ACE] inhibitor, angiotensin II receptor blocker [ARB], 
locker, diuretics, digitalis, calcium channel blocker, hydralazine,
itrate, antiarrhythmics, aspirin, warfarin, and statin), (4) in-
ospital management (diuretics, natriuretic peptides, inotropic
gents, vasodilators, and non-pharmacological procedures), and (5)
n-hospital mortality.rdiology 62 (2013) 95–101
Statistical analysis
Medication use before hospitalization and at discharge was
compared using the McNemar test. Multivariable logistic regres-
sion was performed to determine the predictors of in-hospital
mortality. The covariates including age, sex, etiology of ischemic
heart disease, medical history [hypertension, diabetes mellitus,
atrial ﬁbrillation, prior stroke, and sustained ventricular tachy-
cardia/ventricular ﬁbrillation (VT/VF), NYHA functional class on
admission, left ventricular ejection fraction (LVEF) on admis-
sion, medication use before hospitalization (ACE inhibitor, ARB, 
blocker, diuretics, digitalis, calcium channel blocker, warfarin, and
statin), systolic blood pressure on admission, and laboratory data
on admission (serum sodium concentration, estimated glomerular
ﬁltration rate {eGFR} on admission, hemoglobin concentration, and
BNP)] were used in developing the multivariable logistic regression
model. The predictors of all-cause death were evaluated among
patients with multivariable adjustment. The covariates included in
the multivariable logistic regression model were used in developing
the post-discharge Cox proportional hazard models. SPSS version
16.0J for Windows (Cary, NC, USA) was  used for all statistical anal-
yses.
Results
Patient characteristics
The  mean age of the 1677 studied patients was  70.7 ± 13.5 years
and 59.4% were men  (Table 1). The causes of HF were ischemic
heart disease in 34.0%, valvular heart disease in 28.1%, hypertensive
heart disease in 26.4%, and dilated cardiomyopathy in 17.0%. A total
of 52.1% of patients had hypertension. Approximately half of the
patients had history of prior hospitalization due to HF.
Patient  characteristics included in this study were com-
pared with those in ATTEND, ADHERE, OPTIMIZE-HF, and EHFS-II
(Table 1). The mean age was  comparable among studies ranging
from 70 to 73 years old. Males were predominant sharing 50–60% in
all studies. Ischemic heart disease was  the most predominant cause
of HF in all studies. However, its prevalence in Japanese studies
(34% in the present study and 33% in ATTEND) was  lower than that
in OPTIMIZE-HF (46%) and EHFS-II (54%). The prevalence of other
causes such as valvular heart disease, hypertensive heart disease,
and dilated cardiomyopathy was  similar among studies.
The  prevalence of comorbidities was also similar among stud-
ies such as hypertension (50–70%), diabetes mellitus (30–40%),
dyslipidemia (25–35%), prior stroke (15%), prior myocardial infarc-
tion (20–30%), atrial ﬁbrillation (30–40%), and sustained VT/VF
(5–10%) except for chronic obstructive pulmonary disease (COPD)
being lower in Japanese studies (6% in the present study and 9% in
ATTEND) than those in other western studies (20–30%).
Clinical status on admission
Symptoms  and physical signs on admission are summarized in
Table 2. Most patients had NYHA functional class III or IV symptoms
and 50–80% patients had rales and peripheral edema. Almost all
patients had chest X-rays taken and 79.5% of patients had lung con-
gestion. Pulmonary artery catheter was  used in 17–20% of patients
in Japanese registries whereas it was  5% in ADHERE.
Systolic blood pressure ranged from 132 to 147 mmHg
and diastolic blood pressure from 75 to 79 mmHg. Labora-
tory data were also similar among studies such as serum
creatinine (1.2–1.8 mg/dL), Na (138–140 mequiv./L), hemoglobin
(12–13 g/dL), and plasma B-type natriuretic peptide (BNP)
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Table  1
Patient characteristics.
Characteristics JCARE-CARD
(n = 1677)
ATTEND
(n  = 1110)
ADHERE
(n  = 105,388)
OPTIMIZE-HF
(n  = 48,612)
EHFS-II
(n  = 3580)
Age, yrs (mean ± SD) 70.7 ± 13.5 73 ± 14 72.4 ± 14.0 73.1 ± 14.2 69.9 ± 12.5
Male,  % 59.4 58.9 48 48 61.3
Causes  of heart failure, %
Ischemic 34.0 33.2 25.0 46.0 53.6
Valvular  heart disease 28.1 17.3 23.0 NA 34.4
Hypertensive 26.4 18.4 9.0 23.0 NA
Dilated  cardiomyopathy 17.0 12.7 NA NA 19.3
Medical  history, %
Hypertension  52.1 70.6 73.0 71.0 62.5
Diabetes  mellitus 29.8 34.0 44.0 42.0 32.8
Dyslipidemia  25.8 NA 35.0 32.0 NA
Prior  stroke 16.3 12.0 17.0 16.0 13.3
Renal  dysfunction 11.3 NA 30.0 20.0 16.8
Anemia  20.3 NA 53.0 18.0 14.7
COPD  5.8 9.0 31.0 28.0 19.3
Smoking  37.6 NA 13.0 16.0 NA
Prior  MI 28.3 NA 31.0 22.0 NA
Atrial  ﬁbrillation 34.9 40.0 31.0 31.0 38.7
Sustained  VT/VF 6.8 NA 9.0 5.5 NA
Prior  hospitalization due to HF 50.0 37.4 75.0 88.0 62.9
Procedures,  %
PCI  18.9 NA NA 28.0 NA
CABG  9.3 NA NA (Including
CABG)
NA
PPM 1.3 NA 17.0 15.3 9.1
ICD  2.2 NA 6.0 5.0 NA
CRT  1.7 NA NA 3.3 NA
COPD, chronic obstructive pulmonary disease; MI,  myocardial infarction; VT/VF, ventricular tachycardia/ﬁbrillation; PCI, percutaneous coronary intervention; CABG, coronary
artery  bypass grafting; PPM, permanent pacemaker; ICD, implantable cardioverter deﬁbrillator; CRT, cardiac resynchronization therapy; NA, not available. Data are shown
as  percent or means ± SD.
Table  2
Vital  signs and laboratory data on admission.
JCARE-CARD
(n = 1677)
ATTEND
(n  = 1100)
ADHERE
(n  = 105,388)
OPTIMIZE-HF
(n  = 48,612)
EHFS-II
(n  = 3580)
Vital signs
Heart rate, bpm 87.8 ± 24.4 99 ± 30 NA 86.6 ± 21.5 NA
SBP,  mmHg 134.3 ± 30.3 147 ± 38 143.8 ± 32.6 142.7 ± 32.9 132.1
DBP,  mmHg  75.4 ± 18.2 NA 79 76.4 ± 19.1 NA
NYHA  functional class, %
I 0.9 0.7 NA NA 97.7
II  10.6 12.1 20 NA NA
III  45.8 39.1 44 NA NA
IV  42.7 47.2 32 NA NA
Dyspnea  on effort, % 85.8 NA 89 61 NA
Dyspnea  at rest, % 66.7 NA 34 44 NA
Orthopnea,  % NA 68.5 NA 27.4 NA
Fatigue,  % 58.3 NA 32 22.1 NA
Jugular  venous distension, % 33.8 61.3 28 32.7 NA
III  sound, % 24.5 40.5 NA NA NA
Rale,  % 51.7 77.6 68 NA NA
Edema,  % 53.3 67.7 65 65 NA
Chest  X-ray, %
Lung  congestion, % 79.5 NA 68 NA NA
Pulmonary  artery catheter, % 16.7 20.1 5 4 NA
Laboratory  data
BUN,  mg/dL 26.2 ± 16.7 NA 31.8 ± 21.0 NA NA
Serum  creatinine, mg/dL 1.28 ± 1.03 1.4 ± 1.5 1.8 ± 1.6 1.8 ± 1.6 1.2
eGFR,  mL/min/1.73 m2 52.5 ± 24.6 NA 53.4 ± 32.1 NA NA
Na,  mequiv./L 139.7 ± 4.6 NA NA 138 ± 4.74 NA
Hemoglobin,  g/dL 12.4 ± 4.5 NA 12.4 ± 2.6 12.1 ± 2.0 13.1
Plasma  BNP, pg/mL 878 ± 929 1063 ± 1158 NA 1278.29 ± 1330.29 NA
LVEF,  % 42.5 ± 17.9 NA 37.5 ± 17.2 39.0 ± 17.6 38 ± 15
SBP, systolic blood pressure; DBP, diastolic blood pressure; NYHA, New York Heart Association; BUN, blood nitrogen urea; eGFR, estimated glomerular ﬁltration rate; BNP,
B-type  natriuretic peptide; LV, left ventricular; EF, ejection fraction; NA, not available. Data are shown as percent or means ± SD.
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Table 3
In-hospital management.
JCARE-CARD
(n = 1677)
ATTEND
(n  = 1100)
ADHERE
(n  = 105,388)
OPTIMIZE-HF
(n  = 48,612)
EHFS II
(n  = 3580)
CCU care, % 34.6 NA 18.7 NA 51
Diuretics,  % 95.9 80.4 (i.v.) 70 (i.v.) 66 (i.v.) 92.9
Natriuretic  peptides, %
Carperitide  33.5 69.4 NA NA NA
Nesiritide  NA NA 8 11 NA
Inotropic  agents, %
Digoxin,  i.v. 10.6 6.5 NA NA NA
Digoxin,  p.o. 33.7 NA NA NA NA
Dopamine  20.4 11 NA NA 11.3
Dobutamine  12.7 12.7 NA NA 10.2
Norepinephrine 3.2 6.2 NA NA 2.6
Amrinone  0.7 NA NA NA NA
Milrinone  2.4 2.8 NA NA NA
Olprinone  1.4 0.7 NA NA NA
Vasodilator  agents, % 3
Nitroprusside 0.0 NA NA NA 0.9
Nitroglycerin 14.5 NA NA NA 37.8
Isosorbide  dinitrate 12.1 9.2 NA NA
Mechanical ventilation, % 8.9 11.1 5 NA 13.9
PCI,  % 3.9 9.6 8.1 NA 8.4
CABG,  % 1.0 1.4 NA NA 1.8
Pacemaker,  % 4.3 4.7 NA NA 2.7
Hemopuriﬁcation, % 3.0 NA 5 NA NA
IABP,  % 1.0 3.6 <1 0.3 2.2
PCPS,  % 0.2 0.6 NA NA NA
LVAS,  % 0.1 0.1 NA 0.1 NA
CCU, coronary care unit; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; IABP, intra-aortic balloon pumping; PCPS, percutaneous cardiopul-
monary support; LVAS, left ventricular assist system; NA, not available.
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A900–1300 pg/mL). Echocardiographic mean LVEF was also similar
anging from 38% to 43%.
n-hospital  management
A  total of 34.6% of patients were admitted to the coronary care
nit (CCU) in our registry. Most patients (70–90%) were treated
ith loop diuretics. Carperitide was used in 33.5%. Dopamine and
obutamine were used in about 20% and 10% of patients, respec-
ively. Vasodilators were used in a fourth of patients. Mechanical
entilation was used in 8.9% of patients. The most striking differ-
nce among studies was the higher use of carperitide in Japanese
able 4
edication use before hospitalization and at discharge.
JCARE-CARD
(n = 1677)
(McNemar) ADHERE
(n = 105,38
Before
hospitalization
At
discharge
Before
hospitaliza
ACE inhibitor, % 26.5 36.9 <0.001 41 
ARB,  % 28.9 47.5 <0.001 12 
ACE  inhibitor or ARB, % 51.2 79.0 <0.001 NA 
  blocker, % 22.3 49.8 <0.001 48 
Diuretics,  % 61.0 88.3 <0.001 70 
Loop  diuretics 54.4 78.8 <0.001 NA 
Aldosterone  antagonist 24.1 43.8 <0.001 NA 
Digitalis,  % 26.6 32.6 <0.001 28 
Calcium  channel blocker, % 24.2 24.1 0.852 NA 
Hydralazine, % NA NA NA NA 
Nitrates,  % 22.4 23.2 0.377 26 
Antiarrhythmics, % 13.8 17.5 <0.001 11 
Aspirin,  % 34.5 47.3 <0.001 NA 
Warfarin,  % 27.5 41.9 <0.001 NA 
Statin,  % 16.2 22.0 <0.001 NA 
CE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; NA, not availastudies  (34–69%) compared to lower use of nesiritide in the USA
(8–11%) (Table 3).
Medication  use before hospitalization and at discharge
The use of ACE inhibitors, ARBs, and  blockers signiﬁcantly
increased at discharge compared to that before hospitalization (all
p < 0.001) (Table 4). The same trend was  observed also in other
studies.
In Japan, the use of ACE inhibitors was  lower and ARBs was more
commonly used. In western registries, the use of ACE inhibitors was
higher than that of ARBs (50–70% versus 10%). Similar to EHFS-II,
8)
OPTIMIZE-HF
(n = 48,612)
EHFS-II
(n = 3580)
tion
At
discharge
Before
hospitalization
At
discharge
Before
hospitalization
At
discharge
48 40.0 53 55 71.1
13 12.0 12 9.3 10.4
52 NA NA 63.1 80.2
54 53.0 64 43.2 61.4
75 65.7 NA 71.2 90.1
NA 61.0 NA NA NA
NA 7.0 NA 28.1 47.5
30 23.0 NA 26.6 31.0
24 NA NA 17.8 14.6
NA 3.0 NA NA NA
NA 22.0 NA 27.7 32.9
NA 10.0 NA 12.9 17.6
NA 40.0 NA 42.9 49.4
23 22.7 NA 24 33.1
20 31.8 33 28.4 41.8
ble.
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Table 5
Predictors of in-hospital and long-term mortality.
Variables HR 95% CI p-Value
In-hospital death
Age  ≥75 years 2.225 1.204–4.113 0.011
Systolic blood pressure on
admission <110 mmHg
2.809 1.489–5.297 0.001
Serum sodium
<135  mequiv./mL
2.881  1.460–5.682 0.002
ARB use before admission 0.457 0.214–0.977 0.043
Prior stroke 2.647 1.437–4.874 0.002
Long-term death
Age  ≥75 years 2.518 1.841–3.442 <0.001
eGFR on admission
<50  mL/min/1.73 m2
1.494 1.092–2.044 0.012
Serum sodium on admission
<135  mequiv./mL
1.611  1.072–2.422 0.022
Hemoglobin on admission
<10  g/dL
2.140  1.548–2.957 <0.001
BNP on admission
≥  600 pg/mL
1.556  1.131–2.141 0.007
Diuretics use before
admission
1.691 1.173–2.437 0.005
Digitalis use before
admission
1.500 1.076–2.092 0.017
Warfarin use before
admission
0.674 0.466–0.976 0.036
Prior sustained VT/VF 2.257 1.485–3.429 <0.001
ARB, angiotensin II receptor blocker; eGFR, estimated glomerular ﬁltration rate; BNP,ig. 1. Median length of stay in this study, ATTEND, ADHERE, OPTIMIZE-HF, and
HFS-II.
bout 80% of patients were prescribed an ACE inhibitor or ARB at
ischarge. The use of  blockers at discharge was  slightly lower
n the present study (50%) compared to other western studies
54–64%).
ength of stay and in-hospital mortality
Mean length of stay was 33.9 ± 34.9 days in the present study. It
as comparable to that in ATTEND (31 days), but, longer than that in
PTIMIZE-HF (5.67 ± 5.49 days). Median length of stay reported in
he present study and previous studies is shown in Fig. 1. The most
triking difference was longer length of stay in Japanese registries
15 days in the present study and 21 days in ATTEND) compared to
hat in Western registries (4–9 days).
In-hospital mortality was comparable between the present
tudy (5.6%), ATTEND (7.7%), and other studies from the USA and
urope (3.8% in OPTIMIZE-HF, 4.0% in ADHERE, and 6.7% in EHFS-
I). In the present study, patients who died during the hospital stay
ad signiﬁcantly longer length of stay (average 55.6 ± 72.5 days
ersus 32.6 ± 30.8 days, p = 0.036 and median 32 days versus 25
ays). However, length of stay was not associated with all-cause
ortality after discharge [hazard ratio (HR) 1.002, 95% conﬁdence
nterval (CI) 0.999–1.005, p = 0.157].
redictors  of in-hospital and long-term mortality
Predictors of in-hospital and long-term mortality are shown
n Table 5. Predictors of in-hospital mortality included older age,
ower systolic blood pressure on admission, lower serum sodium
oncentration on admission, and prior stroke. Use of ARBs before
dmission was signiﬁcantly associated with decreased in-hospital
ortality. Predictors of long-term mortality included older age,
ower eGFR, lower serum sodium concentration on admission,
ower hemoglobin concentration on admission, higher BNP on
dmission, diuretic use, digitalis use, and prior sustained VT/VF.
arfarin use before admission was associated with decreased all-
ause mortality after discharge.
iscussion
The present study demonstrated by using the JCARE-CARD
atabase that, among patients hospitalized with worsening HF,
he characteristics, clinical status, and laboratory data on admis-
ion were similar to those previous Japanese and western studies.
anagement was also similar except for higher use of carperitide,
uman atrial natriuretic peptide, and ARB, which, however, was
onsistent with the Japanese registry, ATTEND. The most striking
ifference between Japanese registries and those from the USA
nd Europe was longer length of stay in Japan. In-hospital crude
ortality rate was comparable among studies.
The present results were similar to the data reported previ-
usly in the ATTEND registry. JCARE-CARD studied HF patientsB-type natriuretic peptide; VT/VF, ventricular tachycardia/ﬁbrillation, HR,  hazard
ratio; CI conﬁdence interval.
hospitalized due to worsening symptoms whereas ATTEND evalu-
ated patients with acute HF syndrome. This might result in a higher
prevalence of patients with prior HF hospitalization in the present
study compared to ATTEND (50.0% versus 37.4%). The clinical char-
acteristics of patients hospitalized due to HF were strikingly similar
among ATTEND, ADHERE, OPTIMIZE-HF, EHFS-II, and the present
study. This similarity of the patients might be due to the inclu-
sion of only hospitalized patients with worsening HF. By using the
criteria regarding their symptoms and signs sufﬁciently to be hos-
pitalized for HF, these studies might have enrolled patients with
reasonably uniform status on admission. However, the prevalence
of ischemic heart disease in Japanese studies (34% in the present
study and 33% in ATTEND) was lower than that in OPTIMIZE-HF
(46%) and EHFS-II (54%). The prevalence of COPD was also lower
in Japanese studies (6% in the present study and 9% in ATTEND)
than those in other western studies (20–30%). Therefore, these dif-
ferences suggest that there were still a few clinical characteristics
of patients with HF that might differ among different regions and
races.
Vasodilators, including nesiritide, were recommended at an
early stage for acute HF patients without symptomatic hypoten-
sion or serious obstructive valvular disease [28]. In this study, about
60% of patients had vasodilators. Speciﬁcally, carperitide, approved
in Japan for improving worsening HF, was frequently used as in-
hospital management in the present study. The administration of
low-dose carperitide in patients with acutely decompensated HF
had been demonstrated to improve the long-term (18-months) out-
come [29]. Intermittent infusion of carperitide in out-patients with
advanced HF signiﬁcantly decreased the length and number of hos-
pitalizations without increasing the mortality [30]. In contrast, the
meta-analyses of nesiritide demonstrated its detrimental effects on
survival and renal function [31]. Moreover, the Acute Study of Clin-
ical Effectiveness of Nesiritide in Decompensated HF (ASCEND-HF),
a randomized double-blind placebo-controlled trial of nesiritide for
7141 patients hospitalized with acute HF, demonstrated that it was
not associated with an increase or a decrease in the rate of death and
rehospitalization within 30 days and had a small, nonsigniﬁcant,
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ffect on dyspnea. It did not worsen renal function, but it increased
he rate of hypotension [32].
HF patients in the present study had a lower rate of ACE inhibitor
se and higher use of ARBs. These results are consistent with
he ATTEND registry [13] and also our previous study [22]. Our
tudy compared the long-term outcomes in patients with LV sys-
olic dysfunction by echocardiography (LVEF < 40%) according to
he discharge use of ACE inhibitors (n = 356) or ARBs (n = 372)
nd the clinical characteristics were similar between patients
ith ACE inhibitor and ARB use, except for higher prevalence of
ypertensive etiology and diabetes mellitus. All-cause death and
ehospitalization were similar between ACE inhibitor and ARB
se [22].
The longer length of stay in Japan compared to other coun-
ries might be due to the differences in the healthcare providing
ystem and the continued treatment for comorbidities as well
s the intensive management of risk factors during the hospi-
alization for worsening HF. Longer length of stay might lead
o higher opportunities to optimize the management known
o improve outcomes in HF patients [12]. The patients, who
ied in the hospital, signiﬁcantly had longer length of stay in
he present study. Despite longer length of stay in Japan, in-
ospital mortality was similar to that in Western countries.
urthermore, length of stay was not associated with all-cause
ortality after discharge. These ﬁndings may  indicate bet-
er prognosis of HF patients in Japan compared to Western
ountries.
tudy limitations
Several limitations inherent in the design of the registry should
e considered. First, the deﬁnition of HF and the inclusion crite-
ia of study patients were different between studies. In ATTEND,
n-patients with acute HF who met  the modiﬁed Framingham cri-
eria were enrolled [13]. It excluded patients with acute coronary
yndrome. In ADHERE, acute HF was deﬁned as either new-onset
F or decompensation of chronic, established HF with symptoms
ufﬁcient to warrant hospitalization and patients were identiﬁed
or inclusion from admissions given a discharge diagnosis of HF
ased on International Classiﬁcation of Diseases 9 (ICD-9) cod-
ng [3]. In OPTIMIZE-HF, HF patients eligible for inclusion were
ospitalized for episodes of worsening HF as a primary cause of
ospitalization or with signiﬁcant HF symptoms that developed
uring hospitalization when HF was not the initial reason for
dmission and had ICD-9 HF diagnosis codes [2]. EHFS-II recruited
atients admitted to hospital with dyspnea and veriﬁcation of HF
new-onset acute HF or acute decompensated chronic HF) based
n symptoms and signs of HF and lung congestion on chest X-
ay [9]. In JCARE-CARD, the Framingham criteria of the HF were
sed and included only patients hospitalized with worsening HF
nd excluded patients with new-onset acute HF and HF patients
ith acute coronary syndrome [15]. Second, data were dependent
n the accuracy of documentation and abstraction by individ-
al cardiologists that participated in this study. Third, in-hospital
ortality in the present study and ATTEND was not so differ-
nt from that in ADHERE, OPTIMIZE-HF, and EHFS-II. However,
his comparison may  not be appropriate when this difference
n length of stay is incorporated into consideration. Finally, we
ollected the detailed acute phase data during index hospital-
zation from the selected 1677 patients. Therefore, they might
ot represent the total JCARE-CARD cohort. However, the char-
cteristics, laboratory data, medication use, and in-hospital and
ong-term outcomes did not differ between the present study and
otal cohort. Therefore, we consider that the ﬁndings from 1677
atients should be consistent in the total cohort of patients in
CARE-CARD.
[
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Conclusions
The characteristics, clinical status, and laboratory data on admis-
sion in patients hospitalized with worsening HF were similar
among registries from Japan and other countries including the USA
and Europe. In-hospital mortality was also similar. However, length
of stay was longer in Japan compared to the USA and Europe.
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